Combining PD-1/PD-L1 inhibitors with PARP inhibitors in breast cancer with germline BRCA1/2 mutations and ovarian cancer has acceptable toxicity and potential efficacy [84,85]. Here, BRCA1 is linked to breast carcinoma.